TETRALOGIC PHARMACEUTICALS CORP 4
4 · TETRALOGIC PHARMACEUTICALS CORP · Filed Dec 19, 2013
Insider Transaction Report
Form 4
Reed Douglas MD
Director
Transactions
- Purchase
Common Stock
2013-12-17$7.00/sh+142,857$999,999→ 142,857 total(indirect: See footnote) - Conversion
Common Stock
2013-12-17+780,980→ 923,837 total(indirect: See footnote) - Conversion
Common Stock
2013-12-17$7.00/sh+278,315$1,948,205→ 1,202,152 total(indirect: See footnote) - Conversion
Series C Convertible Stock
2013-12-17−780,980→ 0 total(indirect: See footnotes)→ Common Stock (780,980 underlying) - Exercise of In-Money
Warrants
2013-12-17−7,590→ 0 total(indirect: See footnotes)Exercise: $6.40→ Common Stock (7,590 underlying) - Exercise of In-Money
Common Stock
2013-12-17$6.40/sh+7,590$48,593→ 1,209,742 total(indirect: See footnote) - Conversion
Convertible Notes
2013-12-17−278,315→ 0 total(indirect: See footnotes)Exercise: $7.00→ Common Stock (278,315 underlying)
Footnotes (4)
- [F1]780,980 shares of Series C Convertible Preferred Stock converted to 780,980 shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
- [F2]The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
- [F3]The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
- [F4]The securities are held of record by Hatteras Venture Partners III, L.P. ("HVPIII") and Hatteras Venture Affiliates, L.P. ("HVAIII"). Hatteras Venture Advisors, LLC is the General Partner of HVPIIII. The reporting person, a partner in HVPIII and HVAIII, has voting and investment power over the shares beneficially owned by HVPIII and HVAIII, and disclaims beneficial ownership of the shares beneficially owned by HVPIII and HVAIII, except to the extent of his pecuniary interest therein.